Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
NMDA receptor antagonist
|
| gptkbp:appointed_by |
gptkb:fragrance
intramuscular injection intravenous injection |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
Spravato
Ketalar |
| gptkbp:contraindication |
gptkb:hospital
hypertension psychosis |
| gptkbp:cultural_impact |
known as ' Special K'
used in recreational settings |
| gptkbp:discovered_by |
gptkb:1962
|
| gptkbp:distributor |
pharmaceutical companies
|
| gptkbp:duration |
30 to 60 minutes
up to 24 hours for depression |
| https://www.w3.org/2000/01/rdf-schema#label |
ketamine
|
| gptkbp:ingredients |
C13 H16 Cl N
|
| gptkbp:is_used_for |
gptkb:healthcare_organization
acute pain management treatment-resistant depression |
| gptkbp:legal_issue |
controlled substance
|
| gptkbp:manager |
oral
subcutaneous |
| gptkbp:related_to |
anesthetic agents
psychedelic substances esketamine |
| gptkbp:research_areas |
psychiatry
pain management anesthesiology |
| gptkbp:side_effect |
dizziness
nausea hallucinations increased blood pressure analgesic effect dissociative effect rapid antidepressant effect |
| gptkbp:symptoms |
anxiety
irritability insomnia respiratory depression cardiovascular instability severe sedation |
| gptkbp:tradition |
can develop with repeated use
|
| gptkbp:bfsParent |
gptkb:ALX-0732
|
| gptkbp:bfsLayer |
5
|